Revenue Update on Arbutus Biopharma Corp(NASDAQ:ABUS)

Arbutus Biopharma Corp(NASDAQ:ABUS) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Mar 21, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.38. Analysts had estimated an EPS of $-0.38.

Arbutus Biopharma Corp (ABUS) made into the market gainers list on Fridays trading session with the shares advancing 1.59% or 0.05 points. Due to strong positive momentum, the stock ended at $3.2, which is also near the day’s high of $3.25. The stock began the session at $3.15 and the volume stood at 59,523 shares. The 52-week high of the shares is $5.48 and the 52 week low is $2.35. The company has a current market capitalization of $176 M and it has 5,50,23,207 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Aug 26, 2015, Richard C Jr Henriques (director) purchased 1,000 shares at $6.95 per share price.

Arbutus Biopharma Corp formerly Tekmira Pharmaceuticals Corporation is a Canada-based biopharmaceutical company focused on discovering developing and commercializing a cure for patients suffering from chronic hepatitis B infection a disease of the liver caused by hepatitis B virus (HBV). The Company seeks to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA or cccDNA that is the source of HBV persistence.

Add Comment